Race Oncology treats first patient with RC220 in a milestone quarter

Race Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of bisantrene.

Watch the full interview here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@raceoncology.com T: +61 2 8051 3043
© 2025 Race Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Race Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.